Valuation: Aquestive Therapeutics, Inc.

Market Cap 494M 428M 400M 366M 689M 47.15B 700M 4.69B 1.84B 23.59B 1.86B 1.82B 78.56B P/E 2026 *
-9.73x
P/E 2027 * -10.1x
Enterprise Value 409M 354M 331M 303M 570M 39.04B 579M 3.88B 1.52B 19.53B 1.54B 1.5B 65.05B EV / Sales 2026 *
8.1x
EV / Sales 2027 * 6.87x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+13.58%
1 week+18.20%
Current month+21.24%
1 month+8.74%
3 months+3.22%
6 months+16.06%
Current year-30.65%
1 week 3.65
Extreme 3.65
4.64
1 month 3.56
Extreme 3.56
4.64
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 16/05/2022
Director of Finance/CFO 67 30/12/2020
Compliance Officer - 01/04/2026
Director TitleAgeSince
Chairman 72 31/03/2024
Director/Board Member 60 31/12/2003
Director/Board Member 50 16/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
09/03/26 Free

General Counsel

200,311 0.1642%
09/03/26 Other

Chief Operating Officer

168,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+13.32%+18.20%+16.06%+129.74% 494M
+2.84%+8.11%+90.85%+132.54% 1,057B
+0.34%+2.04%+49.36%+50.79% 625B
-0.29%-0.31%+23.01%+61.35% 435B
+1.58%+4.80%+51.48%+39.79% 363B
+0.65%+1.85%+32.06%+39.99% 296B
+0.79%+4.26%+8.64%+7.42% 249B
+0.77%+8.73%+44.49%+57.19% 222B
+0.34%+1.27%-5.10%-50.94% 209B
-0.00%+1.55%+10.55%+66.48% 165B
Average +2.02%+1.51%+32.14%+53.43% 362.13B
Weighted average by Cap. +1.04%+1.33%+49.09%+66.21%

Financials

2026 *2027 *
Net sales 50.51M 43.73M 40.87M 37.36M 70.39M 4.82B 71.49M 479M 188M 2.41B 190M 186M 8.03B 71.92M 62.26M 58.19M 53.19M 100M 6.86B 102M 682M 268M 3.43B 270M 264M 11.43B
Net income -50.65M -43.85M -40.98M -37.46M -70.58M -4.83B -71.69M -481M -189M -2.42B -190M -186M -8.05B -47.99M -41.55M -38.84M -35.49M -66.89M -4.58B -67.93M -455M -179M -2.29B -180M -176M -7.63B
Net Debt -85M -73.58M -68.78M -62.86M -118M -8.11B -120M -807M -316M -4.06B -319M -312M -13.51B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
10/08/26 US$4.490 +13.96% 5,398,737
07/08/26 US$3.940 +0.51% 1,860,430
06/08/26 US$3.920 +4.39% 1,536,412
05/08/26 US$3.755 +0.40% 1,466,033
04/08/26 US$3.740 -1.32% 2,691,743
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.940USD
Average target price
8.889USD
Spread / Average Target
+125.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock